EE353 Incorporation of Cladribine for Patients With Multiple Sclerosis in a Health Insurance Company in Brazil: Cost-Effectiveness
To assess the cost-effectiveness ratio of Cladribine compared to Natalizumab and Ocrelizumab for patients aged 18 years or older with Highly Active Multiple Sclerosis (HAMS). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: J.M. Alves Junior, F.E. Prota, J.C.B. Martinelli, A. Chrispim, M. Serpeloni, I. Barreto, F.F. Christoforo, B.M. Nascimento, M. Ferreira Source Type: research
EE67 Insurer and Patient Costs for Repeat Breast Surgery After Initial Lumpectomy for Breast Cancer
∼20-25% of patients who undergo a primary lumpectomy for the treatment of breast cancer require a reoperation due to adverse outcomes like positive surgical margins or cancer recurrence. We analyze the economic impact of patients who require repeat breast tissue resection as part of their treatmen t. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: S. Wing, Y. Liu, F. Zheng, J.C. Selber Source Type: research
CO103 Modelled Impact of Nirsevimab for All Infants in Preventing Respiratory Syncytial Virus (RSV): Related Hospitalizations and Costs in the Brazilian Private Healthcare System
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LTRI) in infants and children worldwide and poses a significant concern in Brazil. Palivizumab is covered by Health Insurance Companies for early preterm infants ( (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Falavigna, S.F. Watanabe, J. Santoro, K. Ribeiro, N. Schneider, M. Safadi, R.T. Stein, A. Kieffer, A. Tolardo Source Type: research
Delay in prior authorization of biologic therapy: Another possible cause of healthcare disparity in IBD patients
This study evaluated the approval time for biologics in IBD.METHODS: A chart review of IBD patients seen in a university gastroenterology clinic over 5 years was performed. Patient gender, race, IBD subtype, biologic use, and insurance type were recorded. Insurance type was classified as private or public (Medicaid or Medicare). Biologic agents evaluated included infliximab, adalimumab, vedolizumab and ustekinumab. Length of time to approval (TTA) and length of time to first infusion or administration (TFI) were recorded. Analysis was performed using t-testing, Fisher's exact testing, and ANOVA with significance set at p&l...
Source: Journal of the National Medical Association - November 30, 2023 Category: General Medicine Authors: Vinay Rao Ishaan Dharia Jessica Gibilisco Danielle Kirelik Scott Baumgartner Katherine Negreira Karan Chawla Jenny Dave Samuel Kallus Omar Ali Belfaqeeh Marie L Borum Source Type: research
The Value of Not Intubating Comatose Patients With Acute Poisoning
Imagine if a new multicenter, randomized trial of a pharmaceutical drug found that for every 3 patients treated on presentation to the hospital with a common severe illness, one intubation and an intensive care unit (ICU) admission were prevented. This would be an instant blockbuster drug. Insurers would scramble to reimburse it, and guidelines and quality metrics would be established to facilitate implementation. In the setting of worsening hospital and ICU strain globally, health systems would work rapidly to implement pathways for using this new therapy. For reference, the RECOVERY trial testing the use of dexamethasone...
Source: JAMA - Journal of the American Medical Association - November 29, 2023 Category: General Medicine Source Type: research
A center-based, ambulatory care concept for hidradenitis suppurativa improves patient outcomes and is also cost-effectiveness
CONCLUSION: Treatment costs of HS are substantial and increase with disease severity. The new form of care is cost-effective and is expected to decrease costs in the long run.PMID:38010850 | DOI:10.1080/09546634.2023.2284105 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - November 27, 2023 Category: Dermatology Authors: Marcus Heise Petra Staubach Georgios Nikolakis Lukas Schollenberger Melanie Mauch Marion Burckhardt Marina Zamsheva Alexandra Strobel Gero Langer Falk Bechara Uwe Kirschner Katharina Hennig Christian Kunte Matthias Goebeler Maurizio Podda Stephan Grabbe M Source Type: research
News at a glance: New cancer institute head, NIH ’s applied research tilt, and bias-free clinical algorithms
BIOMEDICINE
U.K. approves CRISPR therapy for sickle cell
In a world first, U.K. regulators last week approved a therapy that uses CRISPR, the Nobel Prize–winning gene-editing tool invented in 2012. The treatment has been shown to help people with beta thalassemia and sickle cell disease, both inherited blood disorders that involve defects in the oxygen-carrying protein hemoglobin. It relies on removing blood stem cells from patients, using CRISPR to turn on the gene for a fetal form of hemoglobin, then reinfusing the cells. The therapy, developed by the companies Vertex Pharmaceuticals and CRISPR T...
Source: Science of Aging Knowledge Environment - November 22, 2023 Category: Geriatrics Source Type: research
Initial prescriptions and medication switches of biological products: an analysis of prescription pathways and determinants in the Swiss healthcare setting
Conclusion
The low number of biosimilar prescriptions, despite the proliferating biosimilar market, indicates a high potential for biosimilar diffusion. The findings indicate that patients typically adhere to the therapy options initially chosen and are less inclined to make changes following the initiation of treatment. Our research highlights the need for awareness initiatives to improve understanding among patients and physicians, enabling informed, shared decision-making about biosimilar prescriptions. (Source: BMJ Open)
Source: BMJ Open - November 21, 2023 Category: General Medicine Authors: Wirth, K., Boes, S., Näpflin, M., Huber, C., Blozik, E. Tags: Open access, Health services research Source Type: research
Lessons from health insurance responses in counteracting COVID-19: a qualitative comparative analysis of South Korea and three influential countries
ConclusionsRegarding where policy support through health insurance should be focused, the workload of medical personnel increased according to the change in the service provision environment due to the pandemic, and the medical service delivery system changed to prevent further infection. Consequently, incentives should be provided to aid the provision of stable services to patients and should be an auxiliary means to implement the national quarantine policy more effectively via a health insurance response system that promptly provides additional financial support in case of future crises. (Source: Archives of Public Health)
Source: Archives of Public Health - November 21, 2023 Category: International Medicine & Public Health Source Type: research
APA Remembers the Mental Health Legacy of Rosalynn Carter
APAreleased a statement today commemorating the life and legacy of Former First Lady Rosalynn Carter, who passed away on Sunday at the age of 96. Throughout her public service career, Mrs. Carter worked tirelessly to improve the quality of life for people with mental illness and substance use disorders. (In the photo at left, she speaks at a special luncheon at APA ’s 1985 Annual Meeting.)“Few, if any, other Americans have been able to accomplish what she did for the cause of mental health,” APA’s statement reads. “She used her bully pulpit to bring the conversation about mental health out from the darkness and a...
Source: Psychiatr News - November 20, 2023 Category: Psychiatry Tags: advocate First Lady Jimmy Carter journalism mental health mental health policy parity Rosalynn Carter stigma The Carter Center Source Type: research
Long-Term Disability Outcomes for Migrants (and Non-migrants) 12 Years Post-injury: Results from the Prospective Outcomes of Injury Study in New Zealand
AbstractTo understand, and identify predictors of, long-term post-injury (i.e. 12 years post-injury) disability outcomes for migrants and non-migrants. This 12-year longitudinal study followed participants with entitlement claim injuries registered with New Zealand’s universal no-fault injury insurer between 2007 and 2009. Information was collected about migrant status, other sociodemographic, health and disability characteristics, and injury characteristics. Disability outcome information was collected 12 years later. Of 1543 people interviewed 12 years post-injury, 1497 had disability and migrant status data availa...
Source: Journal of Immigrant and Minority Health - November 20, 2023 Category: International Medicine & Public Health Source Type: research
